scholarly journals Pediatric screening tools for malnutrition: an update

2020 ◽  
Vol 23 (3) ◽  
pp. 203-209 ◽  
Author(s):  
Jessie M. Hulst ◽  
Koen Huysentruyt ◽  
Koen F. Joosten
2019 ◽  
Author(s):  
Nita Vangeepuram ◽  
Bian Liu ◽  
Po-hsiang Chiu ◽  
Linhua Wang ◽  
Gaurav Pandey

AbstractType 2 diabetes has become alarmingly prevalent among youth in recent years. However, simple questionnaire-based screening tools to reliably identify diabetes risk and prevent the adverse effects of this serious disease are only available for adults, not for youth. As a first step in developing such a tool, we used a large-scale dataset from the National Health and Nutritional Examination Survey (NHANES), to examine the performance of a well-known adult diabetes risk self-assessment screener and published pediatric clinical screening guidelines in identifying youth with pre- diabetes/diabetes (pre-DM/DM) based on American Diabetes Association diagnostic biomarkers. We assessed the agreement between the adult screener/pediatric screening guidelines and biomarker diagnostic criteria by conducting comparisons using the overall data set and sub-datasets stratified by sex, race/ethnicity, and age. While the pediatric guidelines performed better than the adult screener in identifying youth with pre-DM/DM (sensitivity 43.1% vs 7.2%), both are inadequate for general deployment among youth. There were also notable differences in the performance of the pediatric guidelines across subgroups based on age, sex and race/ethnicity. In an effort to improve pre-DM/DM screening, we also evaluated data-driven machine learning-based classification algorithms, several of which performed slightly but statistically significantly better than the pediatric screening guidelines.


2014 ◽  
Vol 71 (6) ◽  
pp. 366-373 ◽  
Author(s):  
Beate Wickop ◽  
Claudia Langebrake

Patienten ab einem Alter von 65 Jahren sind die bedeutendste Zielgruppe der Pharmakotherapie. Die im Alter häufig auftretende Multimorbidität bedingt oft eine Polymedikation. Eine leitliniengerechte Therapie aller Erkrankungen ist problematisch und selten in Studien an älteren Patienten geprüft. Zudem sind im Alter auftretende pharmakokinetische und pharmakodynamische Veränderungen zu beachten. Diese bedingen, dass bestimmte Medikamente für ältere Patienten potentiell inadäquat sind, weil sie ein hohes Risiko für unerwünschte Arzneimittelwirkungen bergen. Zur Identifikation von potentiell inadäquater Medikation wurden mehrere Negativlisten und Screening-Tools entwickelt. Im Artikel werden die START/STOPP-Kriterien, die PRISCUS-Liste, die Österreichische PIM-Liste sowie die FORTA-Einteilung näher erläutert. Der Einsatz dieser Tools kann die Qualität der medikamentösen Therapie im Alter verbessern. Zudem empfiehlt sich ein regelmäßiger Medikationsreview. Die Bestimmung der im Alter meist eingeschränkten Nierenfunktion und eine entsprechende Dosisanpassung der Medikation sowie die Wahl einer niedrigen Einstiegsdosis beim Ansetzen eines neuen Medikamentes bei älteren Patienten können ebenfalls einen Beitrag zur Arzneimitteltherapiesicherheit leisten.


2013 ◽  
Author(s):  
Giselle M. Medina-Velez ◽  
Nydia M. Cappas-Ortiz ◽  
Omar Alicea-Velez ◽  
Angelica Montalvo-Santiago ◽  
Emily M. Perez-Torres ◽  
...  

2015 ◽  
Vol 40 (03) ◽  
Author(s):  
D Eglseer ◽  
AM Eisenberger ◽  
J Bergthaler ◽  
G Wirnsberger ◽  
RE Roller
Keyword(s):  

2004 ◽  
Vol 12 (2) ◽  
pp. 115-125
Author(s):  
Katrin Batereau ◽  
Martin Müller ◽  
Norbert Klaas ◽  
Baldur Barczewski

2017 ◽  
Vol 1 (3) ◽  
pp. 156-160
Author(s):  
Jacqueline Watchmaker ◽  
Sean Legler ◽  
Dianne De Leon ◽  
Vanessa Pascoe ◽  
Robert Stavert

Background: Although considered a tropical disease, strongyloidiasis may be encountered in non-endemic regions, primarily amongst immigrants and travelers from endemic areas.  Chronic strongyloides infection may be under-detected owing to its non-specific cutaneous presentation and the low sensitivity of commonly used screening tools. Methods: 18 consecutive patients with serologic evidence of strongyloides infestation who presented to a single urban, academic dermatology clinic between September 2013 and October 2016 were retrospectively included.  Patient age, sex, country of origin, strongyloides serology titer, absolute eosinophil count, presenting cutaneous manifestations, and patient reported subjective outcome of pruritus after treatment were obtained via chart review.  Results: Of the 18 patients, all had non-specific pruritic dermatoses, 36% had documented eosinophila and none were originally from the United States. A majority reported subjective improvement in their symptoms after treatment. Conclusion:  Strongyloides infection and serologic testing should be considered in patients living in non-endemic regions presenting with pruritic dermatoses and with a history of exposure to an endemic area.Key Points:Chronic strongyloidiasis can be encountered in non-endemic areas and clinical manifestations are variableEosinophilia was not a reliable indicator of chronic infection in this case series Dermatologists should consider serologic testing for strongyloidiasis in patients with a history of exposure and unexplained pruritus


Sign in / Sign up

Export Citation Format

Share Document